par John R. Fischer
, Senior Reporter | March 13, 2019
Ultrasound societies across America and worldwide are calling for the FDA to remove its “black box” designation for ultrasound contrast agent labels.
Expressing their reasoning in a Citizen Petition filed by the International Contrast Ultrasound Society (ICUS), the groups argue that scientific research and studies support UCAs as safe diagnostic imaging products and that the black box misrepresents risks, leading providers to refrain from using the agents in situations where they are medically necessary and making patients apprehensive about using them.
“When the black box was put on the ultrasound contrast agent, there wasn’t enough data to understand their safety,” a spokesperson for ICUS told HCB News. “Since that time, there has been a considerable amount of data that’s been produced worldwide, and a significant amount of clinical experience and growth in the field. It all points to a very strong safety profile for ultrasound contrast agents. As a result of that, the black box misrepresents the level of risk and deters use of agents by some physicians.”
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
An indicator of the highest level of risk associated with products approved by it, the FDA introduced the "black box" for UCAs in 2007. It has since downgraded packaged insert contraindications three times, as well as removed a 30-minute monitoring requirement for patients with pulmonary hypertension or unstable cardiac cardiopulmonary conditions, and approved new indications for use in adults and children, according to the petition.
The societies claim that UCAs reduce the need for unnecessary downstream tests and related costs by improving the reliability of real-time ultrasound scans, as well as speed up diagnosis and access to appropriate therapy, reduce lengths of stay in the hospital and improve patient care, outcomes and experiences.
They also say that safety studies and independent, peer-reviewed journal trials undertaken after 2007 have since validated the safe use of UCAs. In addition, the agents contain no radioactive material or dye, present no known risk of kidney or liver damage, do not require sedation, and can be metabolized and expelled from body within minutes.
“Our collective experience shows that UCAs are exceedingly safe and beneficial, and they can change patient outcomes and improve patient experiences,” said the Society of Radiologists in Ultrasound in a statement, adding that contrast-enhanced ultrasound is often “equivalent to or superior to CT and MRI, yet it is less expensive, more patient-friendly, more widely available, and completely radiation-free.”